SMShun Devan Moodley

Shun Devan Moodley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shun Devan Moodley has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autologous haematopoietic stem cell transplantation in patients with multiple sclerosis: Experience from South Africa

    by A M Setzer, S Dindayal, J Damelin, D Moodley, D Brittain, A McDonald, A Mahomed, A Pincus, J Thomson, J R Du Toit

    Background. Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease that remains a major cause of neurological disability in young adults. While disease-modifying therapies (DMTs) can delay progression, many patients with highly active relapsing- remitting MS (RRMS) continue to experience breakthrough disease. Autologous haematopoietic stem cell transplantation (ASCT) offers durable immune reconstitution and remission but remains underutilised in upper-middle-income settings such as South Africa (SA). Objective. To evaluate the safety, feasibility and clinical outcomes of ASCT for MS in a real-world SA cohort. Methods. We conducted a retrospective record review of all MS patients who underwent ASCT between 1 January 2009 and 31 December 2024 at two JACIE-accredited tertiary centres (Wits Donald Gordon Medical Centre and Netcare Pretoria East Hospital). Data were extracted from institutional transplant records and analysed using descriptive statistics and Kaplan-Meier survival estimates. The primary outcome was the safety of ASCT for MS, and the secondary outcomes were the clinical outcomes of patients who underwent ASCT for MS. Results. Thirty-two patients were included (median age 42 years; 53% female; 94% RRMS). Median disease duration prior to ASCT was 7.4 years, and 97% had received prior DMTs. Conditioning included cyclophosphamide (97%), anti-thymocyte globulin (69%) and fludarabine (34%). The median neutrophil and platelet engraftment occurred at 10 and 14 days, respectively. Relapse-free survival was 100% at 1 year and 91% (95% confidence interval 68 - 98) at 5 years. Approximately 90% of evaluable patients demonstrated neurological improvement or stabilisation at 1 year. Treatment-related adverse events occurred in 63% of cases, and 95% of these side-effects were grade 3 or less: most commonly neutropenic fever (50%) and mucositis (16%). Only 5% of adverse reactions were grade 4, with no transplant-related mortality. Conclusion. ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA. Its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs. The expansion of accredited national ASCT programmes and registry-based outcome monitoring is warranted.

  • Open Access

    Taxpas: Epidemiological and Survival Data in Breast Cancer Patients Treated with a Docetaxel-Based Chemotherapy Regimen in South Africa

    by Shun Devan Moodley, Alicia McMaster, Rashem Mothilal

    Breast cancer is the leading cancer among South African women. There is limited South African epidemiological data on triple-negative breast cancer (TNBC). Taxpas was a nonrandomized observational survey conducted in multiple centres in South Africa from April 2004 to December 2010. 1632 female patients diagnosed with breast cancer, with a median age of 51 years, were enrolled in the survey. Patients were treated on a docetaxel-based chemotherapy regimen. The objective of the study was to assess epidemiological data and survival data. The incidence of TNBC was 14%. The one-year survival rate for the total cohort was 84%. The one-year survival rate for patients with early stage and metastatic breast cancer was recorded as 94% and 65%, respectively. Patients with TNBC stage III (all ages) and stage IV (≤50 years) had statistically significant worse 1-year survival rate compared to N-TNBC patients of the same age and stages. Conclusion. The incidence of TNBC in South Africa which is 14% is comparable to global incidence. The 1-year survival data for certain subgroups supports the literature saying that TNBC carries a worse prognosis compared to N-TNBC. Women ≤50 years diagnosed with late stage TNBC carried the worst prognosis in this survey.